Bioavailability of LY03004 and Risperdal® Consta®
A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
Sponsor: Luye Pharma Group Ltd.
A PHASE1 clinical study on Schizoaffective Disorder and Schizophrenia, this trial is completed. The trial is conducted by Luye Pharma Group Ltd. and has accumulated 7 data snapshots since 2014. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Luye Pharma Group Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .